BR112018011308A2 - anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos - Google Patents
anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmosInfo
- Publication number
- BR112018011308A2 BR112018011308A2 BR112018011308A BR112018011308A BR112018011308A2 BR 112018011308 A2 BR112018011308 A2 BR 112018011308A2 BR 112018011308 A BR112018011308 A BR 112018011308A BR 112018011308 A BR112018011308 A BR 112018011308A BR 112018011308 A2 BR112018011308 A2 BR 112018011308A2
- Authority
- BR
- Brazil
- Prior art keywords
- n3pglu
- amyloid peptide
- beta amyloid
- peptide antibodies
- antibodies
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
os anticorpos para aß de n3pglu humano, composições compreendendo tais anticorpos de aß de n3pglu, e métodos de usar tais anticorpos de aß de n3pglu para o tratamento de uma doença definida pordeposição de aß incluindo doenças de alzheimer clínicas ou pré-clínicas, síndrome de down, e angiopatia amiloide cerebral clínica ou pré-clínica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662279268P | 2016-01-15 | 2016-01-15 | |
| PCT/US2017/012795 WO2017123517A1 (en) | 2016-01-15 | 2017-01-10 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018011308A2 true BR112018011308A2 (pt) | 2018-11-27 |
Family
ID=57966094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018011308A BR112018011308A2 (pt) | 2016-01-15 | 2017-01-10 | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9944696B2 (pt) |
| EP (1) | EP3402817B1 (pt) |
| JP (1) | JP6634158B2 (pt) |
| KR (1) | KR102141969B1 (pt) |
| CN (2) | CN114891100B (pt) |
| AR (1) | AR107290A1 (pt) |
| AU (1) | AU2017207250B2 (pt) |
| BR (1) | BR112018011308A2 (pt) |
| CA (1) | CA3007000C (pt) |
| EA (1) | EA037784B1 (pt) |
| ES (1) | ES2968255T3 (pt) |
| IL (1) | IL259748B2 (pt) |
| JO (1) | JOP20170004B1 (pt) |
| MX (1) | MX2018008557A (pt) |
| TW (1) | TWI634126B (pt) |
| WO (1) | WO2017123517A1 (pt) |
| ZA (1) | ZA201901207B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| PE20212266A1 (es) | 2019-03-26 | 2021-11-30 | Janssen Pharmaceutica Nv | ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
| US20240010713A1 (en) | 2021-01-11 | 2024-01-11 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023076971A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| WO2023077042A1 (en) | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| AR127484A1 (es) | 2021-10-29 | 2024-01-31 | Lilly Co Eli | Compuestos y métodos dirigidos a interleucina-34 |
| CA3236560A1 (en) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Compounds and methods targeting interleukin-34 |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| KR20070040824A (ko) | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
| WO2008011348A2 (en) | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| KR20110036809A (ko) | 2008-06-12 | 2011-04-11 | 아피리스 아게 | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 |
| CA2730073A1 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
| US8795664B2 (en) * | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| AU2014233615B2 (en) * | 2010-08-12 | 2016-08-11 | Eli Lilly And Company | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| EP3042917B1 (en) * | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
-
2017
- 2017-01-03 JO JOP/2017/0004A patent/JOP20170004B1/ar active
- 2017-01-04 TW TW106100110A patent/TWI634126B/zh active
- 2017-01-04 AR ARP170100014A patent/AR107290A1/es unknown
- 2017-01-10 EP EP17703491.5A patent/EP3402817B1/en active Active
- 2017-01-10 WO PCT/US2017/012795 patent/WO2017123517A1/en active Application Filing
- 2017-01-10 US US15/402,268 patent/US9944696B2/en active Active
- 2017-01-10 MX MX2018008557A patent/MX2018008557A/es unknown
- 2017-01-10 IL IL259748A patent/IL259748B2/en unknown
- 2017-01-10 CN CN202210627760.XA patent/CN114891100B/zh active Active
- 2017-01-10 JP JP2018529131A patent/JP6634158B2/ja active Active
- 2017-01-10 CA CA3007000A patent/CA3007000C/en active Active
- 2017-01-10 AU AU2017207250A patent/AU2017207250B2/en active Active
- 2017-01-10 BR BR112018011308A patent/BR112018011308A2/pt unknown
- 2017-01-10 EA EA201891286A patent/EA037784B1/ru unknown
- 2017-01-10 ES ES17703491T patent/ES2968255T3/es active Active
- 2017-01-10 KR KR1020187019854A patent/KR102141969B1/ko active IP Right Grant
- 2017-01-10 CN CN201780006700.3A patent/CN108473566B/zh active Active
-
2019
- 2019-02-26 ZA ZA2019/01207A patent/ZA201901207B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102141969B1 (ko) | 2020-08-06 |
| US9944696B2 (en) | 2018-04-17 |
| EP3402817A1 (en) | 2018-11-21 |
| TWI634126B (zh) | 2018-09-01 |
| MX2018008557A (es) | 2018-09-18 |
| ES2968255T3 (es) | 2024-05-08 |
| ZA201901207B (en) | 2022-05-25 |
| CN108473566A (zh) | 2018-08-31 |
| JP2019507107A (ja) | 2019-03-14 |
| AR107290A1 (es) | 2018-04-18 |
| WO2017123517A1 (en) | 2017-07-20 |
| IL259748B2 (en) | 2023-03-01 |
| EA201891286A1 (ru) | 2018-12-28 |
| CN108473566B (zh) | 2022-06-17 |
| CN114891100B (zh) | 2024-05-03 |
| CA3007000C (en) | 2021-07-27 |
| IL259748A (en) | 2018-07-31 |
| EP3402817B1 (en) | 2023-10-18 |
| KR20180086268A (ko) | 2018-07-30 |
| IL259748B (en) | 2022-11-01 |
| CA3007000A1 (en) | 2017-07-20 |
| JOP20170004B1 (ar) | 2022-09-15 |
| AU2017207250B2 (en) | 2019-04-18 |
| TW201739761A (zh) | 2017-11-16 |
| US20170204171A1 (en) | 2017-07-20 |
| CN114891100A (zh) | 2022-08-12 |
| JP6634158B2 (ja) | 2020-01-22 |
| EA037784B1 (ru) | 2021-05-20 |
| AU2017207250A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
| MX2017000378A (es) | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. | |
| BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| BR112017024714A2 (pt) | métodos para preparação do fator de von willebrand modificado | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| DK3290525T3 (da) | Fremgangsmåde til screening af lægemiddel og terapeutisk mål der anvendes til behandling af alzheimers sygdom | |
| IT201700121764A1 (it) | Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative. | |
| DK3810128T3 (da) | Sammensætninger til behandling og/eller forebyggelse af proteinaggregeringssygdomme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |